"triple-negative" meaning in All languages combined

{
  "etymology_templates": [
    {
      "args": {
        "1": "2004"
      },
      "expansion": "First attested in 2004",
      "name": "etydate"
    }
  ],
  "etymology_text": "First attested in 2004.",
  "forms": [
    {
      "form": "triple negative",
      "tags": [
        "alternative"
      ]
    }
  ],
  "head_templates": [
    {
      "args": {
        "1": "-"
      },
      "expansion": "triple-negative (not comparable)",
      "name": "en-adj"
    }
  ],
  "lang": "English",
  "lang_code": "en",
  "pos": "adj",
  "senses": [
    {
      "categories": [
        {
          "kind": "other",
          "name": "English entries with incorrect language header",
          "parents": [],
          "source": "w"
        },
        {
          "kind": "other",
          "name": "Pages with 1 entry",
          "parents": [],
          "source": "w"
        },
        {
          "kind": "other",
          "name": "Pages with entries",
          "parents": [],
          "source": "w"
        },
        {
          "kind": "other",
          "langcode": "en",
          "name": "Oncology",
          "orig": "en:Oncology",
          "parents": [],
          "source": "w"
        }
      ],
      "examples": [
        {
          "bold_text_offsets": [
            [
              267,
              282
            ]
          ],
          "ref": "2004 July 15, L. A. Carey, C. M. Perou, L. G. Dressler, et al., “Race and the poor prognosis basal breast tumor (BBT) phenotype in the population-based Carolina Breast Cancer Study (CBCS)”, Meeting Abstract: 2004 ASCO Annual Meeting, in Journal of Clinical Oncology, volume 22, number 14, →DOI, abstract number 9510:",
          "text": "Multiple BrCa [breast cancer] microarray datasets (Sorlie et al PNAS 2003; van't Veer et al, Nature 2002; Sotiriou et al, PNAS 2003) suggest that 90% of BBT [basal breast tumor] are ER-negative, PR-negative, and HER-2 nonamplified (Perou C, unpublished). Thus, this “triple negative” phenotype may be used to identify and determine the frequency of BBT.",
          "type": "quotation"
        }
      ],
      "glosses": [
        "Of a breast cancer: characterized by the lack of expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2)."
      ],
      "id": "en-triple-negative-en-adj-8UhAgUyR",
      "links": [
        [
          "oncology",
          "oncology"
        ],
        [
          "breast cancer",
          "breast cancer#English"
        ],
        [
          "expression",
          "expression"
        ],
        [
          "ER",
          "ER"
        ],
        [
          "PR",
          "PR"
        ],
        [
          "HER2",
          "HER2"
        ]
      ],
      "raw_glosses": [
        "(oncology) Of a breast cancer: characterized by the lack of expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2)."
      ],
      "related": [
        {
          "word": "basal-like"
        },
        {
          "english": "triple-negative breast cancer",
          "translation": "triple-negative breast cancer",
          "word": "TNBC"
        }
      ],
      "tags": [
        "not-comparable"
      ],
      "topics": [
        "medicine",
        "oncology",
        "sciences"
      ]
    }
  ],
  "word": "triple-negative"
}

{
  "etymology_templates": [
    {
      "args": {
        "1": "2004"
      },
      "expansion": "First attested in 2004",
      "name": "etydate"
    }
  ],
  "etymology_text": "First attested in 2004.",
  "forms": [
    {
      "form": "triple negative",
      "tags": [
        "alternative"
      ]
    }
  ],
  "head_templates": [
    {
      "args": {
        "1": "-"
      },
      "expansion": "triple-negative (not comparable)",
      "name": "en-adj"
    }
  ],
  "lang": "English",
  "lang_code": "en",
  "pos": "adj",
  "related": [
    {
      "word": "basal-like"
    },
    {
      "english": "triple-negative breast cancer",
      "translation": "triple-negative breast cancer",
      "word": "TNBC"
    }
  ],
  "senses": [
    {
      "categories": [
        "English adjectives",
        "English entries with incorrect language header",
        "English lemmas",
        "English multiword terms",
        "English terms with quotations",
        "English uncomparable adjectives",
        "Pages with 1 entry",
        "Pages with entries",
        "en:Oncology"
      ],
      "examples": [
        {
          "bold_text_offsets": [
            [
              267,
              282
            ]
          ],
          "ref": "2004 July 15, L. A. Carey, C. M. Perou, L. G. Dressler, et al., “Race and the poor prognosis basal breast tumor (BBT) phenotype in the population-based Carolina Breast Cancer Study (CBCS)”, Meeting Abstract: 2004 ASCO Annual Meeting, in Journal of Clinical Oncology, volume 22, number 14, →DOI, abstract number 9510:",
          "text": "Multiple BrCa [breast cancer] microarray datasets (Sorlie et al PNAS 2003; van't Veer et al, Nature 2002; Sotiriou et al, PNAS 2003) suggest that 90% of BBT [basal breast tumor] are ER-negative, PR-negative, and HER-2 nonamplified (Perou C, unpublished). Thus, this “triple negative” phenotype may be used to identify and determine the frequency of BBT.",
          "type": "quotation"
        }
      ],
      "glosses": [
        "Of a breast cancer: characterized by the lack of expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2)."
      ],
      "links": [
        [
          "oncology",
          "oncology"
        ],
        [
          "breast cancer",
          "breast cancer#English"
        ],
        [
          "expression",
          "expression"
        ],
        [
          "ER",
          "ER"
        ],
        [
          "PR",
          "PR"
        ],
        [
          "HER2",
          "HER2"
        ]
      ],
      "raw_glosses": [
        "(oncology) Of a breast cancer: characterized by the lack of expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2)."
      ],
      "tags": [
        "not-comparable"
      ],
      "topics": [
        "medicine",
        "oncology",
        "sciences"
      ]
    }
  ],
  "word": "triple-negative"
}